It can take years before a drug discovery makes it to your local pharmacy. There are basic disease studies that must be performed. There are trials with patients. It must be approved the Food and Drug Administration. And then, a company must agree to manufacture it.
The CTSA awards were created to expedite the process by identifying the obstacles that impede the transformation of basic research discoveries into drugs, treatments or methods for prevention. As an example of a way to promote collaboration among institutions, officials in the UT System have reached an agreement that facilitates multi-site studies at the system's 15 institutions.
"At MD Anderson, the grant has provided critical laboratory support for our Clinical and Translational Research Center," said Daniel Karp, M.D., who is a co-principal investigator of CCTS and a professor in MD Anderson Cancer Center's Department of Investigational Cancer Therapeutics. "The CTSA has also helped support innovations in bioinformatics, robust tumor banking and important community initiatives - especially in the critical areas of nutrition, obesity and liver disease."
"In the previous five years, we saw much progress that has provided direct benefit for our patients, strengthened our research infrastructure and built important bridges between our thought leaders," Karp said. "This renewal will allow us to go forward and accelerate the contributions of our team science."
Robert C. Bast, Jr., M.D., co- investigator for the CTSA program at UTHealth and vice president for Translational Research at MD Anderson Cancer Center, said, "Renewal of this grant allows the CTSA to continue to encou
'/>"/>
| Contact: Robert Cahill Robert.Cahill@uth.tmc.edu 713-500-3030 University of Texas Health Science Center at Houston Source:Eurekalert |